SCHEDULE 13G/A: Orca Capital AG Discloses 3.7% Stake in Dogwood Therapeutics Following Recent Offering

Orca Capital AG has filed an amended Schedule 13G, reporting a 3.7% beneficial ownership stake in Dogwood Therapeutics, Inc. as of March 14, 2025, following the issuer's recent registered offering.

Summary

• Orca Capital AG, a German entity, reported beneficial ownership of 69,821 shares of Dogwood Therapeutics, Inc. common stock.
• This stake represents 3.7% of the total 1,911,128 shares of Common Stock outstanding.
• The ownership percentage is calculated based on shares outstanding immediately after Dogwood Therapeutics' registered offering, as described in their Prospectus Supplement filed on March 14, 2025.
• Orca Capital AG holds sole voting power and sole dispositive power over all 69,821 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change or update to a previously filed statement.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing disclosing an institutional ownership stake. While not directly positive or negative about the company's performance, the presence of an institutional investor can be seen as a neutral to slightly positive signal of market participation.

Positives

• The filing indicates an institutional investor, Orca Capital AG, holds a significant stake in Dogwood Therapeutics, Inc., which can be interpreted as a sign of investor confidence.

Negatives

• The reported stake of 3.7% is below the 5% threshold typically associated with activist investor positions, suggesting Orca Capital AG does not currently intend to influence or change control of the issuer, as certified in the filing.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Dogwood Therapeutics, Inc.'s future performance or outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Thomas Konig, Director of Orca Capital AG)

Industry Context

This filing indicates an institutional investor's position in a therapeutics company. It is a routine disclosure of a passive investment stake and does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership and potential investor confidence in Dogwood Therapeutics, Inc.

Key Dates

Keywords

Dogwood Therapeutics, Orca Capital AG, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional investor, equity stake